Let's take a deep dive into CBD.
No, not the stuff that gets you high--that's THC. Instead, let's focus on cannabidiol.
"Unlike a lot of the cannabis companies that are currently in this space, we are not focused on the THC-side of the business--the psychoactive part of the plant. We instead are focused on cannabidiol, or CBD, which is not psychoactive," said Joseph Dowling, CEO of CV Sciences.
Cannabidiol is, as Dowling told Zev Fima, the non-psychoactive part of marijuana. TheStreet's Steve Fiorillo took an in-depth look at CBD and its effects. He wrote that "some studies suggest it may work to counteract some of the more negative THC effects, like paranoia and heightened anxiety. For this reason, often people that are looking for legal weed with THC will look for a strain with a solid THC to CBD ratio, chasing an ideal, centered high."
Some effects, according to Fiorillo, include anti-inflammatory effects, and neuroprotective properties.
"CBD has been linked to treatment in degenerative muscle conditions, depression, injury rehabilitation, chronic pain disorders, acne, high blood pressure and a bevy of other diseases and disorders. The scope of treatments CBD has been linked to in a limited number of studies is impressive," wrote Fiorillo.
CBD is a budding industry. A New Frontier Data report in August suggested that the CBD industry could hit $2 billion by 2022.
For the first time, CBD derived from hemp surged ahead of marijuana-derived CBD in 2017. New Frontier expects "to see continued changes as the pharmaceutical sector officially opens in 2018. By 2022, the hemp-derived CBD market is expected to be worth $646 million, while the marijuana-derived market will grow to $647 million.
"The U.S. CBD market is primed for expansive growth across its three primary sectors, hemp-derived CBD, marijuana-derived CBD and pharmaceutical CBD...We project that by 2022, each of these three sectors will account for approximately one-third of the $1.9 billion total market," said Giadha Aguirre de Carcer, CEO of New Frontier Data.
TheStreet's Annie Gaus has also reported on CBD. In fact, she attended the CBD Expo West to take a look at the industry.
Gaus has also reported on how CBD may eclipse the pot industry.
"Many people in the business believe that CBD is a groundbreaking treatment for everything from opiate addiction and depression to PTSD -- and that, without the stigma of a federal prohibition such as the one that exists for marijuana, it might be more palatable to the wider public and possibly even to regulators," wrote Gaus.
CV Sciences doesn't specialize in medical CBD. Instead, it focuses on oils.
This interview was sponsored by CV Sciences.